Imatinib Sandoz

Imatinib, the active ingredient in Imatinib Sandoz, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with sourcing from the European Union market and ensuring quality and regulatory compliance.

Imatinib is a targeted tyrosine kinase inhibitor used in hematologic and solid tumor malignancies.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and achieves durable cytogenetic and molecular responses. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission induction and improves survival when combined with chemotherapy. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth and delays disease progression in patients with KIT or PDGFRA mutations.

Adverse reactions may occur with imatinib therapy.

Common Side Effects: - Nausea - Edema - Fatigue - Diarrhea

Serious or Rare Side Effects: - Neutropenia - Hepatotoxicity - Cardiac failure

Before and during treatment, clinicians should observe several safety measures.

- Monitor blood counts: regular CBC to detect cytopenias. - Assess liver function: periodic LFTs for hepatotoxicity. - Evaluate cardiac status: baseline and periodic ECG for heart‑failure risk. - Avoid use in patients with known hypersensitivity to imatinib. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Imatinib may interact with several concomitant medicines.

Major Interactions (Avoid): - CYP3A4 strong inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib exposure. - CYP3A4 strong inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: imatinib may enhance anticoagulant effect; monitor INR. - Proton pump inhibitors: may modestly affect gastric pH and absorption; observe clinical response.